Entrada reports Phase 1/2 ELEVATE — 45 — 201 Cohort 1 data showing ENTR — 601 — 45 meets safety, tolerability goals in Duchenne muscular dystrophy trial
Entrada Therapeutics released positive topline results already reported from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study in Duchenne muscular dystrophy. The initial-dose cohort met the main goal on safety and tolerability, supporting continued dose escalation in later cohorts. Early biological activity was observed,